Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

VELOUR studies are anticipated in the first half of 2011.  Based on projected event rates, an interim analysis of the VENICE study is expected to be conducted by an Independent Data Monitoring Committee in mid-2011, with final results anticipated in 2012.  

In addition, a randomized Phase 2 study (AFFIRM) is evaluating aflibercept as a 1st-line treatment for metastatic colorectal cancer in combination with FOLFOX (folinic acid [leucovorin], 5-fluorouracil, and oxaliplatin).  The AFFIRM study is fully enrolled, and initial data are anticipated in the second half of 2011.

Monoclonal AntibodiesSince 2007, Regeneron and sanofi-aventis have collaborated on the discovery, development, and commercialization of fully human monoclonal antibodies generated by Regeneron using its VelocImmune® technology.  During the fourth quarter of 2009, Regeneron and sanofi-aventis expanded and extended their collaboration with the objective to advance an average of four to five antibodies into clinical development each year between 2010 and 2017.  The following eight antibody candidates are currently in clinical development under the collaboration:

REGN727, an antibody to Proprotein Convertase Substilisin/Kexin type 9 (PCSK9), a novel target for LDL cholesterol ("bad cholesterol") reduction, has been evaluated in Phase 1 studies using both intravenous and subcutaneous routes of administration.  REGN727 is being studied as a single agent and in combination with statin therapy.  Phase 2 studies have been initiated in patients with hypercholesterolemia.  

REGN88, an antibody to the interleukin-6 receptor (IL-6R), is in a Phase 2/3 study in rheumatoid arthritis and a Phase 2 study in ankylosing spondylitis, a form of arthritis that primarily affects the spine.  Both studies are enrolling patients, and initial Phase 2 results are expected in 2011.

REGN421, an antibody to
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 GenomeDx Biosciences today announced data ... Society for Radiation Oncology (ASTRO) Annual Meeting demonstrate ... a genomic test capable of predicting aggressiveness of ... patient outcomes for prostate cancer patients following surgery. ... published study that demonstrates how Decipher test results ...
(Date:9/15/2014)... -- Patients in today,s changing health care landscape are receiving ... setting versus a hospital. In an effort to stay ... continue to receive high quality medical care; Kaiser Permanente ... medicine residency program. The program,s progressive curriculum will prepare ... even virtual settings. "We are excited ...
(Date:9/15/2014)... N.J. , Sept. 15, 2014 /PRNewswire-iReach/ -- ... , University of South Carolina, submitted a Citizen ... Commissioner, asking the FDA to add another Black ... drug labels.  This request asks for a Black ... "toxic psychoses, hallucinations, paranoia, suicidal thoughts or acts, ...
Breaking Medicine Technology:Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3
... PARSIPPANY, N.J., March 31, 2011 Pacira Pharmaceuticals, Inc. ... company, today announced financial results for the fourth quarter ... on the execution of its pre-commercial and launch strategies ... "Since our initial public offering in February, we have ...
... CardioNexus Corporation ( www.cardionexus.com ) an affiliated ... Panasonic CardioHealth® Station at the 2011 Annual Scientific ... device, which has just received clearance from the ... and portable cardiovascular imaging device which aims to ...
Cached Medicine Technology:Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 2Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 3Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 4Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 5Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 6Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 7Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 8Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 9Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results 10Breakthrough CardioHealth® Station Cleared By FDA to Take Center Stage at the Annual Scientific Sessions of the American College of Cardiology 2011 2Breakthrough CardioHealth® Station Cleared By FDA to Take Center Stage at the Annual Scientific Sessions of the American College of Cardiology 2011 3Breakthrough CardioHealth® Station Cleared By FDA to Take Center Stage at the Annual Scientific Sessions of the American College of Cardiology 2011 4
(Date:9/16/2014)... (PRWEB) September 16, 2014 The rapidly ... concern for health plans, employers and PBMs as spending ... of their drug lists. Once a concentrated, patient-specific practice, ... 25 webinar from Atlantic Information Services, Inc. (AIS), ... will offer details of what one leading health ...
(Date:9/16/2014)... San Diego, CA (PRWEB) September 16, 2014 ... a new hydrating lip gloss that true-ly pampers lips from ... your lips satin-smooth all day. , “The creation of true ... were suffering from dry, dehydrated lips no matter what products ... that not only looked great on, but could actually hydrate ...
(Date:9/16/2014)... Triad Semiconductor, Inc. today announced that David ... former President of Linear Technology Corporation was appointed to ... technology and business expertise, and we are delighted that ... Hayden, Triad CEO and chairman. , Mr. Bell brings ... semiconductor experience to Triad's board. From 2008 to 2012, ...
(Date:9/15/2014)... St. Louis, Missouri (PRWEB) September 16, 2014 ... injury lawyers at Carey Danis & Lowe ... Boston Scientific Corp., was found responsible for the injuries ... their bladder sling to treat stress urinary incontinence (SUI). ... that practices defective medical device litigation and personal injury ...
(Date:9/15/2014)... 2014 iFitDress.com, one of the most distinguished ... sapphire evening dresses to its online store. In ... top quality products. They are now provided at very low ... senior spokesman has confidence in the newly unveiled sapphire evening ... by customers from all over the world. Up to now, ...
Breaking Medicine News(10 mins):Health News:Sept. 25 Webinar to Offer Health Plan, Employer Strategies to Control Compounded Medication Costs 2Health News:True Science Cosmetics, LLC Launches True Lipz™ 2Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Beautiful Sapphire Evening Dresses Provided By iFitDress.com 2
... of,Public Welfare said today it is working with ... an abandoned child in,Lansdowne, Delaware County., An ... noon today and said, "I left a baby ... without providing any other information. Local law,enforcement was ...
... and large numbers of men, are interested in having cosmetic ... Journal of Plastic and Reconstructive Surgery. , ... in cosmetic surgery, liposuction or both, and another 23 percent ... Among men, 23 percent said they would be interested in ...
... /PRNewswire/ - The IND proposes a randomized Phase,III ... Best Supportive,Care (BSC) versus BSC alone for the ... gastroesophageal junction and stomach who,have failed adjuvant or ... of the IND and will direct the clinical ...
... Oct. 26 In a statewide,effort to help ... violence shelters, the Michigan State Medical Society (MSMS),Foundation ... and,distribute personal care items in conjunction with the ... Day" on,Saturday, October 27., "The women and ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... UniCare announced today a policy to,make it easy for ... the prescription drugs they need. A one-time override ... up so,that UniCare policyholders in the affected counties can ... in place for,members living in Los Angeles, Orange, San ...
Cached Medicine News:Health News:Safe Haven Hotline Receives Report of Abandoned Baby in Lansdowne 2Health News:Huge numbers willing to go under knife to alter their appearance, study finds 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Michigan State Medical Society Foundation 'Makes A Difference' by Assisting Those in Crisis Shelters 2Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires 2
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
... phakic IOL is the first lens of its ... for the reduction or elimination of myopia in ... diopters and in patients aged 21 and over. ... 150,000 procedures performed worldwide, results prove that the ...
... the strongest vacuum force in ... The unit includes a ... plug, footswitch, built-in wheels, retractable ... ring to hold the liquid ...
... technology for the phakic eye, clinically ... quality of vision and visual acuity ... lens is compatible with current cataract ... for the correction of myopia in ...
Medicine Products: